FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323350630> ?p ?o ?g. }

• W4323350630 endingPage "27" @default.
• W4323350630 startingPage "26" @default.
• W4323350630 abstract "Abstract Background The incidence of inflammatory bowel disease (IBD) continues to rise rapidly among Canadian children. The care of children results in higher direct healthcare costs than adults with IBD. It is imperative that we identify individuals who will become the highest-cost users of the health system in order to intervene early and decrease the individual- and system-level burden of IBD. Purpose To develop a predictive-model for high-cost health system users and (2) identify factors associated with high-cost healthcare use. Method Incident cases of IBD diagnosed ≤17y residing in Ontario and enrolled in the Canadian Children IBD Network (CIDsCaNN) between Dec 31 2013 and Jan 31 2019 were linked deterministically using health card number to health administrative data. Using a validated algorithm, direct healthcare costs accumulated between the 31st and 365th day after diagnosis were calculated using data from CIDsCaNN (medications) and health administrative data (health system encounters, including surgery). A predictive model was created to determine high-cost (≤25th percentile) and medium-cost (26th to 75th) users, compared to low-cost users (&gt;75th) using ordinal logistic regression. Potential predictive variables were determined a priori based on clinical significance and magnitude of univariable association, based on sample size-informed degrees of freedom. Variables from CIDsCaNN data included: IBD type, age at diagnosis, sex, first line of therapy (steroids, aminosalicylates, exclusive enteral nutrition; yes or no, not mutually exclusive), disease activity (severe vs. moderate vs. none/mild based on PUCAI [UC] or wPCDAI [Crohn’s]). Predictive variables from the health administrative data included: rural/urban residence, hospitalization at diagnosis, intestinal resection or colectomy within 3 months of diagnosis, emergency department visit ±1 month of diagnosis, and a mental health encounter within the first year following diagnosis. Anti-TNF treatment was excluded from models due to the strong correlation with the outcome (direct costs). Overall model fit was estimated with a c-statistic. Result(s) Among the 487 (57% Crohn’s) children included in the study, the mean (sd) direct costs accumulated between the 31st and 365th days following IBD diagnosis was $14,451 (14,665). The mean cost among high-cost users was $33,533 (16,530); medium-cost users, $11,038 (5322); low-cost users, $2530 (831). The predictive model identified high-cost users of the health system with acceptable model fit (c-statistic 0.69). The relative contribution of individual variables, as measured by odds ratio (OR), is reported in the Table. Image Conclusion(s) The direct healthcare costs of pediatric IBD are substantial. Children with IBD who become high-cost users of the health system were identifiable using characteristics at diagnosis (e.g., need for mental health care, emergency visits, older age). Further research should assess whether interventions in patients at-risk for becoming high-cost users may help to reduce costs. Please acknowledge all funding agencies by checking the applicable boxes below Other Please indicate your source of funding; Ontario Academic Health Sciences Centres Alternate Funding Plan Innovation Fund Disclosure of Interest E. Kuenzig: None Declared, R. Duchen: None Declared, T. Walters Grant / Research support from: Janssen, Abbvie, Psfizer, Ferring, Amgen, Consultant of: Janssen, Abbvie, Psfizer, Ferring, Amgen, D. Mack: None Declared, A. Griffiths Grant / Research support from: Abbvie, Consultant of: Abbvie, Amgen, BristolMyersSquibb, Janssen, Lilly, Takeda, Speakers bureau of: Abbvie, Janssen, Takeda, C. Bernstein Grant / Research support from: Research grants from Abbvie Canada, Amgen Canada, Pfizer Canada, and Sandoz Canada and contract grants from Janssen, Abbvie and Pfizer, Consultant of: Abbvie Canada, Amgen Canada, Bristol Myers Squibb Canada, JAMP Pharmaceuticals, Janssen Canada, Pfizer Canada, Sandoz Canada, Takeda, Speakers bureau of: Abbvie Canada, Janssen Canada, Pfizer Canada and Takeda Canada, G. Kaplan Grant / Research support from: Ferring, Consultant of: AbbVie, Janssen, Pfizer, Amgen, Sandoz, Pendophram, and Takeda, Speakers bureau of: AbbVie, Janssen, Pfizer, Amgen, Sandoz, Pendophram, and Takeda, A. Otley Grant / Research support from: Research support: AbbVie Global. Research site: AbbVie, Pfizer, Eli-Lily, Janssen, Consultant of: AbbVie Canada, W. Yu: None Declared, X. Wang: None Declared, J. Guan: None Declared, S. Fung: None Declared, E. Benchimol Consultant of: McKesson Canada, Dairy Farmers of Ontario (unrelated to medications used to treat inflammatory bowel disease)" @default.
• W4323350630 created "2023-03-08" @default.
• W4323350630 creator A5000558036 @default.
• W4323350630 creator A5002602317 @default.
• W4323350630 creator A5014465832 @default.
• W4323350630 creator A5019018783 @default.
• W4323350630 creator A5021680772 @default.
• W4323350630 creator A5024735969 @default.
• W4323350630 creator A5028767797 @default.
• W4323350630 creator A5029532155 @default.
• W4323350630 creator A5029904644 @default.
• W4323350630 creator A5041797468 @default.
• W4323350630 creator A5043272946 @default.
• W4323350630 creator A5058943068 @default.
• W4323350630 creator A5078398991 @default.
• W4323350630 date "2023-03-01" @default.
• W4323350630 modified "2023-10-04" @default.
• W4323350630 title "A182 PREDICTING HIGH DIRECT HEALTHCARE COSTS IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN THE FIRST YEAR FOLLOWING DIAGNOSIS" @default.
• W4323350630 doi "https://doi.org/10.1093/jcag/gwac036.182" @default.
• W4323350630 hasPublicationYear "2023" @default.
• W4323350630 type Work @default.
• W4323350630 citedByCount "3" @default.
• W4323350630 countsByYear W43233506302023 @default.
• W4323350630 crossrefType "journal-article" @default.
• W4323350630 hasAuthorship W4323350630A5000558036 @default.
• W4323350630 hasAuthorship W4323350630A5002602317 @default.
• W4323350630 hasAuthorship W4323350630A5014465832 @default.
• W4323350630 hasAuthorship W4323350630A5019018783 @default.
• W4323350630 hasAuthorship W4323350630A5021680772 @default.
• W4323350630 hasAuthorship W4323350630A5024735969 @default.
• W4323350630 hasAuthorship W4323350630A5028767797 @default.
• W4323350630 hasAuthorship W4323350630A5029532155 @default.
• W4323350630 hasAuthorship W4323350630A5029904644 @default.
• W4323350630 hasAuthorship W4323350630A5041797468 @default.
• W4323350630 hasAuthorship W4323350630A5043272946 @default.
• W4323350630 hasAuthorship W4323350630A5058943068 @default.
• W4323350630 hasAuthorship W4323350630A5078398991 @default.
• W4323350630 hasBestOaLocation W43233506301 @default.
• W4323350630 hasConcept C105795698 @default.
• W4323350630 hasConcept C122048520 @default.
• W4323350630 hasConcept C126322002 @default.
• W4323350630 hasConcept C151956035 @default.
• W4323350630 hasConcept C160735492 @default.
• W4323350630 hasConcept C162324750 @default.
• W4323350630 hasConcept C187212893 @default.
• W4323350630 hasConcept C2778260677 @default.
• W4323350630 hasConcept C2779134260 @default.
• W4323350630 hasConcept C2779280984 @default.
• W4323350630 hasConcept C33923547 @default.
• W4323350630 hasConcept C50522688 @default.
• W4323350630 hasConcept C71924100 @default.
• W4323350630 hasConceptScore W4323350630C105795698 @default.
• W4323350630 hasConceptScore W4323350630C122048520 @default.
• W4323350630 hasConceptScore W4323350630C126322002 @default.
• W4323350630 hasConceptScore W4323350630C151956035 @default.
• W4323350630 hasConceptScore W4323350630C160735492 @default.
• W4323350630 hasConceptScore W4323350630C162324750 @default.
• W4323350630 hasConceptScore W4323350630C187212893 @default.
• W4323350630 hasConceptScore W4323350630C2778260677 @default.
• W4323350630 hasConceptScore W4323350630C2779134260 @default.
• W4323350630 hasConceptScore W4323350630C2779280984 @default.
• W4323350630 hasConceptScore W4323350630C33923547 @default.
• W4323350630 hasConceptScore W4323350630C50522688 @default.
• W4323350630 hasConceptScore W4323350630C71924100 @default.
• W4323350630 hasIssue "Supplement_1" @default.
• W4323350630 hasLocation W43233506301 @default.
• W4323350630 hasLocation W43233506302 @default.
• W4323350630 hasOpenAccess W4323350630 @default.
• W4323350630 hasPrimaryLocation W43233506301 @default.
• W4323350630 hasRelatedWork W2025062623 @default.
• W4323350630 hasRelatedWork W2290181619 @default.
• W4323350630 hasRelatedWork W2357611842 @default.
• W4323350630 hasRelatedWork W2383988748 @default.
• W4323350630 hasRelatedWork W2389709268 @default.
• W4323350630 hasRelatedWork W2896139880 @default.
• W4323350630 hasRelatedWork W3209514756 @default.
• W4323350630 hasRelatedWork W4200003514 @default.
• W4323350630 hasRelatedWork W4207046311 @default.
• W4323350630 hasRelatedWork W4383420693 @default.
• W4323350630 hasVolume "6" @default.
• W4323350630 isParatext "false" @default.
• W4323350630 isRetracted "false" @default.
• W4323350630 workType "article" @default.